The use of LCMV-specific T cell hybridomas for the quantitative analysis of MHC class I restricted antigen presentation
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Journal of Immunological Methods ; 237 (2000), 1-2. - S. 199-202. - ISSN 0022-1759. - eISSN 1872-7905
- Klassifikation
-
Biowissenschaften, Biologie
- Ereignis
-
Veröffentlichung
- (wo)
-
Konstanz
- (wer)
-
Bibliothek der Universität Konstanz
- (wann)
-
2000
- Urheber
-
Schwarz, Katrin
Broek, Maries F. van den
Giuli, Rita de
Seelentag, Wolfhart
Shastri, Nilabh
Groettrup, Marcus
- URN
-
urn:nbn:de:bsz:352-221682
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:01 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Schwarz, Katrin
- Broek, Maries F. van den
- Giuli, Rita de
- Seelentag, Wolfhart
- Shastri, Nilabh
- Groettrup, Marcus
- Bibliothek der Universität Konstanz
Entstanden
- 2000
Ähnliche Objekte (12)
Chaperone BAG6 is dispensable for MHC class I antigen processing and presentation
Evidence for an involvement of the ubiquitin‐like modifier ISG15 in MHC class I antigen presentation
Evidence for an involvement of the ubiquitin-like modifier ISG15 in MHC class I antigen presentation
PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines
The immunoproteasome in antigen processing and other immunological functions
The ubiquitin-like modifier FAT10 in antigen processing and antimicrobial defense
Editorial Overview: Molecular immunology : targeting the immune system
Recent insights how combined inhibition of immuno/proteasome subunits enables therapeutic efficacy
No essential role for tripeptidyl peptidase II for the processing of LCMV-derived T cell epitopes
Subunit specific inhibitors of proteasomes and their potential for immunomodulation
Advances in Prostate Cancer Immunotherapies
On the Role of the Immunoproteasome in Protein Homeostasis
Chaperone BAG6 is dispensable for MHC class I antigen processing and presentation
Evidence for an involvement of the ubiquitin‐like modifier ISG15 in MHC class I antigen presentation
Evidence for an involvement of the ubiquitin-like modifier ISG15 in MHC class I antigen presentation
PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines
The immunoproteasome in antigen processing and other immunological functions
The ubiquitin-like modifier FAT10 in antigen processing and antimicrobial defense
Editorial Overview: Molecular immunology : targeting the immune system
Recent insights how combined inhibition of immuno/proteasome subunits enables therapeutic efficacy
No essential role for tripeptidyl peptidase II for the processing of LCMV-derived T cell epitopes
Subunit specific inhibitors of proteasomes and their potential for immunomodulation
Advances in Prostate Cancer Immunotherapies
On the Role of the Immunoproteasome in Protein Homeostasis
Chaperone BAG6 is dispensable for MHC class I antigen processing and presentation
Evidence for an involvement of the ubiquitin‐like modifier ISG15 in MHC class I antigen presentation
Evidence for an involvement of the ubiquitin-like modifier ISG15 in MHC class I antigen presentation
PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines
The immunoproteasome in antigen processing and other immunological functions
The ubiquitin-like modifier FAT10 in antigen processing and antimicrobial defense
Editorial Overview: Molecular immunology : targeting the immune system
Recent insights how combined inhibition of immuno/proteasome subunits enables therapeutic efficacy
No essential role for tripeptidyl peptidase II for the processing of LCMV-derived T cell epitopes
Subunit specific inhibitors of proteasomes and their potential for immunomodulation
Advances in Prostate Cancer Immunotherapies